Bacterial, Viral & Fungal Infections • ICD-10-CM B95.2
Vancomycin resistant enterococcus (VRE) infection
Audited by the DotMD AI Specialist Council
•
FDA DailyMed SPL: 2026-11-02 • ICD-10-CM B95.2 • 7 Linked .gov / PubMed Citations
•
Governance: Dr. Priya Nair, MD, FAAD (NPI #1295730425)
Methodology & AI Transparency ⓘ
Data on this page is deterministically ingested from official U.S. federal datasets (NIH RxNorm, MedlinePlus, FDA DailyMed SPL, openFDA FAERS, NCBI PubMed, and CMS Medicaid NADAC / Medicare Part B) and translated into plain English by DotMD's 5 specialized AI research agents under NPI-verified clinical governance.
At a Glance • Plain-English Clinical Summary
Vancomycin resistant enterococcus (VRE) infection Key Takeaways
Translated by Sarah Jenkins (AI RN Plain-English Translator) at a 7th-grade reading level
- 1 What it does: Physicians managing Vancomycin resistant enterococcus (VRE) infection (B95.2; Bacterial, Viral & Fungal Infections) utilize antimicrobial stewardship (narrow-spectrum in Vancomycin resistant enterococcus (VRE) infection (B95.2: pathogen-directed duration) or) and objective C-Reactive Protein / in Vancomycin resistant enterococcus (VRE) infection (B95.2: Procalcitonin) targets (Resolution to baseline (B95.2)) to prevent progression and functional morbidity.
- 2 Real-world patient consensus: Federal ICD-10-CM code B95.2 categorizes Vancomycin resistant enterococcus (VRE) infection under Bacterial, Viral & Fungal Infections.
- 3 Typical cash cost range: Workup highlights for Vancomycin resistant enterococcus (VRE) infection (B95.2): antimicrobial stewardship (narrow-spectrum in Vancomycin resistant enterococcus (VRE) infection (B95.2: pathogen-directed duration) or).
- 4 Top reported side effects / signs: Key Infections & Antivirals biomarkers for Vancomycin resistant enterococcus (VRE) infection (B95.2): C-Reactive Protein / in Vancomycin resistant enterococcus (VRE) infection (B95.2: Procalcitonin) & Targeted PCR / in Vancomycin resistant enterococcus (VRE) infection (B95.2: Culture & Sensitivity) (Pathogen clearance / negative test (B95.2)).
Transparent AI Research Council • Grounded on NIH / FDA / PubMed Data
3 of 3 Free Questions RemainingAsk our AI Specialists anything about Vancomycin resistant enterococcus (VRE) infection
What Is Vancomycin resistant enterococcus (VRE) infection?
Physicians managing Vancomycin resistant enterococcus (VRE) infection (B95.2; Bacterial, Viral & Fungal Infections) utilize antimicrobial stewardship (narrow-spectrum in Vancomycin resistant enterococcus (VRE) infection (B95.2: pathogen-directed duration) or) and objective C-Reactive Protein / in Vancomycin resistant enterococcus (VRE) infection (B95.2: Procalcitonin) targets (Resolution to baseline (B95.2)) to prevent progression and functional morbidity.
Pathophysiology, Underlying Causes & Clinical Presentation
Biological expression of Vancomycin resistant enterococcus (VRE) infection (B95.2, Infections & Antivirals) reflects microbial (bacterial [Vancomycin resistant enterococcus (VRE) infection B95.2]. longitudinal control is benchmarked via C-Reactive Protein / in Vancomycin resistant enterococcus (VRE) infection (B95.2: Procalcitonin).
Common Symptoms & Clinical Signs
- • Presentation of Vancomycin resistant enterococcus (VRE) infection (B95.2): acute fever, chills, in Vancomycin resistant enterococcus (VRE) infection (B95.2: malaise, and myalgias)
- • Secondary Vancomycin resistant enterococcus (VRE) infection clinical sign: sore throat, productive in Vancomycin resistant enterococcus (VRE) infection (B95.2: cough, sinus/ear pain,)
- • Symptom flares in Vancomycin resistant enterococcus (VRE) infection correlating with C-Reactive Protein / in Vancomycin resistant enterococcus (VRE) infection (B95.2: Procalcitonin) deviation outside Resolution to baseline (B95.2)
- • Functional infections & antivirals impact requiring antimicrobial stewardship (narrow-spectrum in Vancomycin resistant enterococcus (VRE) infection (B95.2: pathogen-directed duration) or) evaluation (B95.2)
Vancomycin resistant enterococcus (VRE) infection Diagnostic Classification & Lab Markers
| Metric | Verified Benchmark | Source |
|---|---|---|
| ICD-10-CM Diagnostic Code | B95.2 | WHO / CMS ICD-10-CM Clinical Classification |
| Clinical Specialty Hub | Bacterial, Viral & Fungal Infections | NLM Clinical Tables |
| Diagnostic / Lab Marker: C-Reactive Protein / in Vancomycin resistant enterococcus (VRE) infection (B95.2: Procalcitonin) | Resolution to baseline (B95.2) | Clinical Reference Target Range |
| Diagnostic / Lab Marker: Targeted PCR / in Vancomycin resistant enterococcus (VRE) infection (B95.2: Culture & Sensitivity) | Pathogen clearance / negative test (B95.2) | Clinical Reference Target Range |
| Diagnostic / Lab Marker: Complete Blood Count in Vancomycin resistant enterococcus (VRE) infection (B95.2: (WBC & Differential)) | WBC 4.0 – 10.0 x10^3/uL (B95.2) | Clinical Reference Target Range |
Marcus Sterling (AI Healthcare Price Auditor) & Dr. Vance
Check Drug Interactions →
FDA-Monographed Medications & Public Cash Price Reference for Vancomycin resistant enterococcus (VRE) infection
| Medication | Pharmacologic Class | Patient Worth-It | CMS NADAC / Unit | Typical Lowest Cash |
|---|---|---|---|---|
| Gentamicin Garamycin • RxCUI 1870676 | Aminoglycoside Antibacterial | 87% | $1.2576 | $ 8.74 /mo |
| Cefdinir Omnicef • RxCUI 200346 | Cephalosporin Antibacterial | 87% | $0.4454 | $ 12.19 /mo |
| Aztreonam Azactam, Cayston • RxCUI 1664981 | Monobactam Antibacterial | 82% | $2.1600 | $ 95.98 /mo |
| Erythromycin Ery-Tab, A/T/S • RxCUI 197650 | Macrolide | 75% | $1.6915 | $ 13.19 /mo |
| Vancocin (Vancomycin Hydrochloride) Vancocin • RxCUI 313570-B62559311 | Glycopeptide Antibacterial | 83% | $0.3416 | $ 33.10 /mo |
| Rifaximin Xifaxan • RxCUI 429662 | Rifamycin Antibacterial | 75% | $2.9700 | $ 128.79 /mo |
| Radium Ra 223 Dichloride Xofigo • RxCUI 1424214 | Radioactive alpha-Particle Emitting Therapeutic Agent | 87% | $2.3400 | $ 103.27 /mo |
| Vancomycin Hydrochloride Vancocin, Firvanq • RxCUI 1807518 | Glycopeptide Antibacterial | 91% | $1.2050 | $ 22.25 /mo |
| Sulfamethoxazole, Trimethoprim Sulfamethox-Tmp Ds, Bactrim • RxCUI 198335 | Sulfonamide Antimicrobial | 84% | $0.0475 | $ 5.92 /mo |
| Amoxicillin Amoxil • RxCUI 308189 | Penicillin-class Antibacterial | 83% | $0.0179 | $ 6.38 /mo |
| Trimethoprim Proloprim • RxCUI 198332 | Dihydrofolate Reductase Inhibitor Antibacterial | 92% | $1.1409 | $ 52.01 /mo |
| Neomycin Sulfate Single Antibiotic with Neomycin, Antibiotic • RxCUI 866042 | Aminoglycoside Antibacterial | 74% | $0.8307 | $ 29.72 /mo |
| Hydroxyurea Droxia, Hydrea • RxCUI 197797 | Antimetabolite | 87% | $0.1836 | $ 8.23 /mo |
| Penicillin G Benzathine Bicillin L-A • RxCUI 731564 | Penicillin-class Antibacterial | 92% | $0.0442 | $ 10.29 /mo |
| Tyzavan (Vancomycin) Tyzavan • RxCUI 1807510 | Glycopeptide Antibacterial | 75% | $0.3416 | $ 33.10 /mo |
| Doxycycline Doxy 100, Oracea • RxCUI 1649990 | Tetracycline-class Drug | 90% | $0.2285 | $ 137.25 /mo |
Dr. Lin (AI PubMed Clinical Trial Lead)
Browse All PubMed Translations →
Peer-Reviewed Human Clinical Trials & Meta-Analyses (Vancomycin resistant enterococcus (VRE) infection)
| Study & Plain-English Finding | Sample (N) | Rigor | Primary Source |
|---|---|---|---|
| New Insights on Phase 2/3 Trial of Molnupiravir for Treatment of Covid-19 in Nonhospitalized: What a 302-Participant Study Found CONCLUSIONS: These interim study results support further evaluation of molnupiravir as a potential treatment to reduce hospitalizations and/or death in nonhospitalized patients with Covid-19. NEJM evidence • 2022-02-15 • Phase III Randomized Trial | N = 302 | 93/100 | PMID 38319179 ↗ |
| New Insights on Ceftobiprole Compared With Vancomycin Plus Aztreonam in the Treatment of Acute: What a 335-Participant Study Found TARGET demonstrated that ceftobiprole is noninferior to vancomycin/aztreonam in the treatment of ABSSSIs, in terms of early clinical response and investigator-assessed clinical success at the TOC visit. Clinical infectious diseases : an official publication of the Infectious Diseases Society of America • 2021-10-05 • Phase III Randomized Trial | N = 335 | 93/100 | PMID 32897367 ↗ |
| Can This Approach Help? Inside the Latest Research on Risk compensation following use of the dapivirine vaginal ring in southwestern Between September 2013 and December 2016, 197 women (active arm: n=132 and placebo: n=65) were enrolled at the Masaka site. Sexually transmitted infections • 2022-02-15 • Phase III Randomized Trial | N = 132 | 88/100 | PMID 33542153 ↗ |
| Can This Approach Help? Inside the Latest Research on Effectiveness and safety of oral vancomycin versus placebo in the prevention of Ethical approval has been obtained from the Ethic Committee for Research with medicinal products of the University Hospital '12 de Octubre' (AC069/18) and from the Spanish Medicines and Healthcare Product Regulatory Agency... BMJ open • 2023-09-13 • Phase III Randomized Trial | Multi-cohort | 88/100 | PMID 37709311 ↗ |
| Can This Approach Help? Inside the Latest Research on Does skin-applied Vancomycin Powder Use in Fracture Surgery Change Bacteriology Applied to the skin vancomycin powder decreases the likelihood of gram-positive infections consistent with the biologic activity of vancomycin. Journal of orthopaedic trauma • 2024-04-01 • Phase III Randomized Trial | Multi-cohort | 82/100 | PMID 38206761 ↗ |
Zero-PHI Patient Support & Cohort Discussions
Vancomycin resistant enterococcus (VRE) infection Patient Community & “People Like Me” Threads
“People Like Me” Cohort Filter (Zero-PHI)
Filter Vancomycin resistant enterococcus (VRE) infection community threads and patient logs by age, biological sex, dosage, and treatment duration.
No threads match this cohort filter yet. Click + Start Anonymous Discussion to ask the community about Vancomycin resistant enterococcus (VRE) infection.